Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

JAGXNeutralEarningsShort Term

High materiality7/10

Jaguar Health Reports Second Quarter 2026 Financials

StockNews.AIAug 19, 4:00 PM EDT1 source

Trading thesisImportance 7/10

Bullish on MVID NDA progress; expect upside into 2027 as NDA submission nears.

AI summary

What happened and why it matters

Jaguar Health reported Q2 2026 results and highlighted a strategic shift to Future Pak for US marketing of Mytesi and Canalevia-CA1, plus ongoing crofelemer development for rare intestinal failure. ESPGHAN 2026 data show crofelemer can reduce parenteral support in MVID by 48%, with a clinical package expected by end-2026 and NDA submission in Q2 2027, potentially reshaping Jaguar’s revenue mix and valuation.

ESPGHAN 2026 data show crofelemer reduces parenteral support in MVID by 48%.
Future Pak licensing shifts US revenue flow and marketing leverage away from Jaguar.
NDA timing for MVID targets end-2026 readiness and Q2 2027 submission.
Q2 2026 results show net loss of $12.69M and non-GAAP EBITDA of -$8.38M.

Sentiment rationale

Materiality rests on NDA timing and ESPGHAN data; however, revenue mix shift to Future Pak reduces visible US cash flows and elevates execution risk, tempering near-term upside.

Key facts

01
Future Pak US license locks marketing for Mytesi and Canalevia-CA1. Upfront $16M.
02
Napo remains crofelemer manufacturer; $2M holdback of upfront fee.
03
US revenue redirected to Future Pak under a royalty-free license from Jan 12, 2026.
04
Q2 2026 prescription product net revenue about $1.2M; YoY down 60%.
05
ESPGHAN 2026 shows crofelemer adjunctive therapy reduces parenteral support by 48% in MVID.

Earnings

Category: Earnings. The report centers on Q2 2026 results and strategic licensing changes, with a near-term catalyst from MVID CROFELEMER NDA timing and ESPGHAN data; relevant for medium-term valuation rerating as NDA milestones approach.